For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Scientific Program

FP163

4686

Dr.Vardhineedi Satya Amrita
Membership No Author Name Email Mobile
4686 Dr.Vardhineedi Satya Amrita dramritaditya@gmail.com 8489632361
Glaucoma

“Small Tube, Big Impact: Early Clinical Experience with ACP ST 250”

Ahmed Clear Path ST 250 is novel GDD with limited data.To evaluate its clinical outcomes in refractory glaucoma.Prospective interventional case series of 20 eyes for 5 months at 2 centers.Outcomes measures: reduction in IOP,medication burden,BCVA.Mean follow up period: 9.6 weeks (0.5-19). Mean Pre-& Postop IOP: 29.45+/-9.33mmHg & 15.45+/-5.61mmHg, with average reduction of 14(5 -30)mmHg (P<0.0001). Mean number of antiglaucoma medications reduced from Preop 3.80+/-1.32 to Postop 0.8+/-0.95, on an average 4 drugs to <1 drug(P=0.0001). BCVA ranged from 1.02+/-1.00 Preop to 1.01+/-1.01 Postop(P=0.5754).No significant complication, except self-limiting hypotony noted in 1 eye.6 eyes needed Supramid suture removal following which mean IOP reduction of 9.8 (1–22) mmHg was noted. Complete success was achieved in 50% eyes, qualified success in 35%, failure in 15%. ACP ST 250 is a safe device for effective IOP control, reshaping the trajectory of refractory glaucoma management.

Membership No Author Name Email Mobile
530 Dr.Gowri Jayadev Murthy gowrijmurthy@gmail.com 919886840172
2274 Dr.Priyanka Sudhakar priyanka89.vims@gmail.com 9035106537
2321 Dr.Meghana Hiremath meghana.rh@gmail.com 9986746540